Please assess the completion status of the following clinical trial:

Trial Title: Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Is 8 to 17 years of age, inclusive, at the time of randomization/initiation of study drug administration.~2. Has received a diagnosis of type 1 diabetes (T1D) according to the criteria from the American Diabetes Association.~3. Is able to be randomized and initiate study drug within 6 weeks (42 days) of the formal T1D diagnosis.~4. Has a peak stimulated C-peptide of ≥0.2 pmol/mL from a mixed meal tolerance test (MMTT) at screening.~5. Has a positive result on testing for T1D-related autoantibodies.~Exclusion Criteria:~1. Has any autoimmune disease other than T1D with the exception of stable thyroid or celiac disease.~2. Has an active infection and/or fever.~3. Has a history of or serologic evidence at screening of current or past infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV).~4. An individual who has a medical, psychological or social condition that, in the opinion of the Principal Investigator, would interfere with safe and proper completion of the trial.

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Teplizumab (Type: EXPERIMENTAL): Teplizumab was administered via intravenous infusion in two courses, with the first course starting on Day 1 (Week 1) and the second course approximately 6 months later at Day 182 (Week 26). Participants who were unable to receive the second 12-day course due to COronaVIrus Disease of 2019 (COVID-19) pandemic restrictions were given the second course at approximately 12 months (Week 52 visit). Each course of treatment included daily infusions for 12 days.~Each course included:~* Day 1: 106 μg/m\^2~* Day 2: 425 μg/m\^2~* Days 3-12: 850 μg/m\^2 Total per course: 9.0 mg/m\^2 The doses of study drug were calculated based on the participant's body surface area (BSA) measured on the first day of each treatment course.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo was administered via intravenous infusion in two courses, with the first course starting on Day 1 (Week 1) and the second course approximately 6 months later at Day 182 (Week 26). Participants who were unable to receive the second 12-day course due to COronaVIrus Disease of 2019 (COVID-19) pandemic restrictions were given the second course at approximately 12 months (Week 52 visit). Each course of treatment included daily infusions for 12 days.~The placebo solution consisted of the same formulation as the study drug but without teplizumab. Placebo was administered in the same dose volume and by the same treatment schedule as the active drug.

Based on this trial design, predict the completion outcome and termination type (if applicable).